Noveris Health SciencesMYCOF 23 Quick Ratio is 0.48 as of Mar. 2026, which is at its 10-year median of 0.48. GuruFocus rates MYCOF with a GF Score™ of 23/100. Among 994 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 89.24% on this metric.
Noveris Health Sciences has a quick ratio of 0.48. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Noveris Health Sciences's Quick Ratio or its related term are showing as below:
MYCOF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.48 Max: 5.31
Current: 0.48
During the past 13 years, Noveris Health Sciences's highest Quick Ratio was 5.31. The lowest was 0.01. And the median was 0.48.
MYCOF's Quick Ratio is ranked worse than 89.24% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs MYCOF: 0.48
Noveris Health Sciences (OTCPK:MYCOF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Noveris Health Sciences Quick Ratio Related Terms
Noveris Health Sciences Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Noveris Health Sciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a Quick Ratio of 0.48 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Noveris Health Sciences and its competitors. This is near median its historical median of 0.48. Over the past decade, Noveris Health Sciences' Quick Ratio has ranged from 0.01 to 5.31. According to the industry distribution chart, Noveris Health Sciences ranks #887 out of 994 companies in the Drug Manufacturers industry, placing it in the top 89.2%.
Is Noveris Health Sciences' Quick Ratio too high?
Noveris Health Sciences' current Quick Ratio of 0.48 is near median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 5.31. The Drug Manufacturers industry median Quick Ratio is 1.45. Noveris Health Sciences' value of 0.48 is 66.9% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #887 out of 994 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #887 out of 994 companies for Quick Ratio. This places Noveris Health Sciences in the lower half of its industry. The industry median Quick Ratio is 1.45. Noveris Health Sciences' value of 0.48 is 66.9% below this benchmark. Historically, Noveris Health Sciences' own Quick Ratio has ranged from 0.01 to 5.31 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 1.45, Noveris Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current Quick Ratio of 0.48 is 66.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Quick Ratio is 0.48, which is near median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Noveris Health Sciences (MYCOF) has a current Quick Ratio of 0.48. The current Quick Ratio is 0.48, which is near median its 10-year median of 0.48 and 66.9% below the Drug Manufacturers industry median of 1.45. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Quick Ratio is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
